Maravai Lifesciences Holdings Inc (MRVI) Gross Profit Margin starting from the third quarter 2026 to third quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Maravai Lifesciences Holdings Inc   (NASDAQ: MRVI)


Maravai Lifesciences Holdings Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MRVI Gross Profit Margin (Sep 30 2026)
Q3 		(Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Revenue Change 12.78 %
Seq. Revenue Change -10.87 %
Revenue In Millions $45.85
Gross Profit Margin 35.31 %
Gross Profit Margin Total Ranking # 1667
Gross Profit In Millions $16.19
Y / Y Gross Profit Change 186.33 %
Seq. Gross Profit Change -21.59 %


Commenting Third Quarter 2026 Gross Profit Margin
Maravai Lifesciences Holdings Inc experienced contraction in Gross Profit by -21.59 % to $46 millions and Revenue by -10.87 %, while Gross Profit Margin fell to 35.31 %, below company*s average Gross Profit Margin.


Observing third quarter 2026 results within Major Pharmaceutical Preparations industry 113 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 1667, from total ranking in the previous quarter at 2944.
Learn about Gross Margin
MRVI's Gross Profit Margin third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 114
Healthcare Sector # 304
Overall # 1654

Gross Profit Margin Statistics
High Average Low
84.55 % 52.51 % 13.91 %
(Jun 30 2022)   (Sep 30 2025)


MRVI Gross Income Trends • More of MRVI's Profitabilty Ratios • MRVI Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
MRVI's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
MRVI's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for MRVI's Competitors
Gross Profit Margin Profit Margin for Maravai Lifesciences Holdings Inc 's Suppliers
Gross Profit Margin Profit Margin for MRVI's Customers

You may also want to know
MRVI's Annual Growth Rates MRVI's Profitability Ratios MRVI's Asset Turnover Ratio MRVI's Dividend Growth
MRVI's Roe MRVI's Valuation Ratios MRVI's Financial Strength Ratios MRVI's Gross Profit Growth
MRVI's Roa MRVI's Inventory Turnover Ratio MRVI's Growth Rates MRVI's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 30 2026 MRQ Gross ProfitSep 30 2026 MRQ Revenue
Ardelyx inc   96.44 %$ 123.116  Millions$ 127.655  Millions
Uniqure N v   95.46 %$ 4.960  Millions$ 5.196  Millions
Agios Pharmaceuticals Inc   95.44 %$ 52.860  Millions$ 55.385  Millions
Zevra Therapeutics Inc   95.25 %$ 35.962  Millions$ 37.756  Millions
Bridgebio Pharma Inc   94.21 %$ 332.721  Millions$ 353.171  Millions
Gyre Therapeutics Inc   94.09 %$ 30.987  Millions$ 32.934  Millions
Vanda Pharmaceuticals Inc   94.05 %$ 65.663  Millions$ 69.815  Millions
Axsome Therapeutics Inc   93.14 %$ 241.887  Millions$ 259.691  Millions
Tonix Pharmaceuticals Holding Corp   92.74 %$ 15.982  Millions$ 17.234  Millions
Urogen Pharma Ltd   91.57 %$ 81.499  Millions$ 89.001  Millions
Arcutis Biotherapeutics Inc   91.34 %$ 131.459  Millions$ 143.919  Millions
Roivant Sciences Ltd   90.47 %$ 31.774  Millions$ 35.121  Millions
Kiniksa Pharmaceuticals International Plc  90.29 %$ 258.211  Millions$ 285.970  Millions
Aurinia Pharmaceuticals Inc   90.08 %$ 75.393  Millions$ 83.699  Millions
Acadia Pharmaceuticals Inc   89.75 %$ 307.201  Millions$ 342.291  Millions
Mannkind Corporation  88.99 %$ 90.657  Millions$ 101.870  Millions
Regeneron Pharmaceuticals Inc   88.79 %$ 4,542.200  Millions$ 5,115.800  Millions
Beone Medicines Ltd   88.52 %$ 1,672.919  Millions$ 1,889.815  Millions
Xeris Biopharma Holdings Inc   88.41 %$ 94.796  Millions$ 107.225  Millions
United Therapeutics Corporation  88.10 %$ 733.400  Millions$ 832.500  Millions
Supernus Pharmaceuticals inc   88.09 %$ 199.753  Millions$ 226.771  Millions
Aclaris Therapeutics Inc   87.24 %$ 1.292  Millions$ 1.481  Millions
Ligand Pharmaceuticals Incorporated  87.04 %$ 68.541  Millions$ 78.746  Millions
Rhythm Pharmaceuticals Inc   86.79 %$ 79.962  Millions$ 92.128  Millions
Rigel Pharmaceuticals Inc  86.67 %$ 70.107  Millions$ 80.890  Millions
Newamsterdam Pharma Company N v   86.11 %$ 16.503  Millions$ 19.164  Millions
Indivior Pharmaceuticals Inc   85.67 %$ 305.000  Millions$ 356.000  Millions
Insmed Inc  85.09 %$ 446.213  Millions$ 524.428  Millions
Vertex Pharmaceuticals Inc  84.71 %$ 2,914.700  Millions$ 3,440.800  Millions
Eli Lilly And Company  83.88 %$ 20,464.000  Millions$ 24,397.000  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.